Miniatura

Fitxers

s41408-022-00778-3.pdf (2.12 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-01-05

Llicència de publicació

cc by (c) Piñana, José Luis et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/193135

One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1038/s41408-022-00778-3

Resum

The long-term clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has been little explored. A prospective multicenter registry-based cohort study conducted from December 2020 to July 2022 by the Spanish Transplant and Cell Therapy group, was used to analyze the relationship of antibody response over time after full vaccination (at 3-6 weeks, 3, 6 and 12 months) (2 doses) and of booster doses with breakthrough SARS-CoV-2 infection in 1551 patients with hematological disorders. At a median follow-up of 388 days after complete immunization, 266 out of 1551 (17%) developed breakthrough SARS-CoV-2 infection at median of 86 days (range 7-391) after full vaccination. The cumulative incidence was 18% [95% confidence interval (C.I.), 16-20%]. Multivariate analysis identified higher incidence in chronic lymphocytic leukemia patients (29%) and with the use of corticosteroids (24.5%), whereas female sex (15.5%) and more than 1 year after last therapy (14%) were associated with a lower incidence (p < 0.05 for all comparisons). Median antibody titers at different time points were significantly lower in breakthrough cases than in non-cases. A serological titer cut-off of 250 BAU/mL was predictive of breakthrough infection and its severity. SARS-CoV-2 infection-related mortality was encouragingly low (1.9%) in our series. Our study describes the incidence of and risk factors for COVID-19 breakthrough infections during the initial vaccination and booster doses in the 2021 to mid-2022 period. The level of antibody titers at any time after 2-dose vaccination is strongly linked with protection against both breakthrough infection and severe disease, even with the Omicron SARS-CoV-2 variant.

Matèries

COVID-19, SARS-CoV-2, Vacunació, Hematologia

Matèries (anglès)

COVID-19, Vaccination, Hematology, SARS-CoV-2

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

PIÑANA, José luis, VAZQUEZ, Lourdes, CALABUIG, Marisa, LÓPEZ CORRAL, Lucía, MARTIN MARTIN, Gabriel, VILLALON, Lucia, SANZ LINARES, Gabriela, CONESA GARCIA, Venancio, SÁNCHEZ SALINAS, Andrés, GAGO, Beatriz, FACAL, Ana, RISCO GÁLVEZ, Irene, OLAVE, María t., ESPIGADO, Ildefonso, LÓPEZ JIMÉNEZ, Javier, HERNÁNDEZ RIVAS, José ángel, AVENDAÑO PITA, Alejandro, ARROYO, Ignacio, FERRER, Elena, GARCÍA CADENAS, Irene, GONZÁLEZ SANTILLANA, Clara, ROLDÁN PÉREZ, Alicia, FERRER, Blanca, GUERREIRO, Manuel, SUAREZ LLEDÓ, María, CAMARA, Angela, CAMPOS BELTRÁN, Diana, NAVARRO, David, CEDILLO, Ángel, SUREDA, Anna, SOLANO, Carlos, MARTINO, Rodrigo, Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. _Blood Cancer Journal_. 2023. Vol. 13, núm. 8. [consulta: 20 de gener de 2026]. ISSN: 2044-5385. [Disponible a: https://hdl.handle.net/2445/193135]

Exportar metadades

JSON - METS

Compartir registre